Serum vasohibin‑1 and chitinase 3‑like protein 1 in chronic kidney disease: level changes and prognostic value
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
ObjectiveTo evaluate changes in serum vasohibin-1 (VASH‑1) and chitinase 3‑like protein 1 (CHI3L1) in patients with chronic kidney disease(CKD) and to assess their prognostic significance.MethodsThis study enrolled 102 CKD patients treated at Xi'an People's Hospital between October 1, 2020 and October 31, 2023, and 102 age‑ and sex‑matched healthy volunteers from the same period as controls. Serum VASH‑1 and CHI3L1 concentrations were quantified by enzyme-linked immunosorbent assay(ELISA). ROC curve analysis assessed the predictive performance of each biomarker and their combination for CKD prognosis. Logistic regression identified independent prognostic factors. Decision curve analysis (DCA) evaluated the clinical net benefit of single versus combined biomarker testing across a range of risk thresholds.ResultsMean serum VASH‑1 and CHI3L1 were significantly higher in CKD patients than controls[VASH‑1: (3164.21±452.15) ng/L vs (2245.35±421.62) ng/L; CHI3L1: (2721.32±354.35) ng/L vs (1853.26±317.43) ng/L; t=15.011, 18.428; P
Fields of Study & Subjects
Chronic Kidney Disease and Diabetes
Dialysis and Renal Disease Management
Acute Kidney Injury Research
Publication details
- Journal / source
- DOAJ (DOAJ: Directory of Open Access Journals)
- Publication date
- 1 March 2026
- Language
- ZH